ES2136883T3 - Nueva formulacion mejorada de aminoglucosido para administracion en forma de aerosol. - Google Patents

Nueva formulacion mejorada de aminoglucosido para administracion en forma de aerosol.

Info

Publication number
ES2136883T3
ES2136883T3 ES95937397T ES95937397T ES2136883T3 ES 2136883 T3 ES2136883 T3 ES 2136883T3 ES 95937397 T ES95937397 T ES 95937397T ES 95937397 T ES95937397 T ES 95937397T ES 2136883 T3 ES2136883 T3 ES 2136883T3
Authority
ES
Spain
Prior art keywords
aminoglycoside
aerosol
aminoglucoside
administration
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95937397T
Other languages
English (en)
Other versions
ES2136883T7 (es
Inventor
Arnold L Smith
Bonnie W Ramsey
Alan B Montgomery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pathogenesis Corp
Seattle Childrens Hospital
Original Assignee
Pathogenesis Corp
Seattle Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23269063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2136883(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pathogenesis Corp, Seattle Childrens Hospital filed Critical Pathogenesis Corp
Application granted granted Critical
Publication of ES2136883T3 publication Critical patent/ES2136883T3/es
Publication of ES2136883T7 publication Critical patent/ES2136883T7/es
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Cosmetics (AREA)

Abstract

SE PRESENTA UNA FORMULACION DE AMINOGLUCOSIDO PARA SU SUMINISTRO POR AEROSOLIZACION. LA FORMULACION CONCENTRADA DE AMINOGLUCOSIDO CONTIENE UNA CANTIDAD EFICAZ DE AMINOGLUCOSIDO CAPAZ DE INHIBIR ENTRE UN 95 Y UN 100% DE BACTERIAS SUSCEPTIBLES. EL AMINOGLUCOSIDO SE FORMULA EN UNA SOLUCION DE 5 ML DE UN CUARTO DE SOLUCION SALINA NORMAL QUE TIENE UN PH DE ENTRE 5.5 Y 6.5. EL METODO ES UTIL PARA EL TRATAMIENTO DE INFECCIONES ENDOBRONQUIALES MEDIANTE UNA FORMULACION SUMINISTRADA COMO UN AEROSOL QUE TIENE UN DIAMETRO DE MASA MEDIO PREDOMINANTEMENTE DE ENTRE 1 Y 5 MICRONES, PRODUCIDO POR UN CHORRO O UN NEBULIZADOR ULTRASONICO.
ES95937397T 1994-10-19 1995-10-17 Nueva formulación mejorada de aminoglucósido para administración en forma de aerosol. Active ES2136883T7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/325,705 US5508269A (en) 1994-10-19 1994-10-19 Aminoglycoside formulation for aerosolization
US325705 2006-01-05

Publications (2)

Publication Number Publication Date
ES2136883T3 true ES2136883T3 (es) 1999-12-01
ES2136883T7 ES2136883T7 (es) 2012-06-14

Family

ID=23269063

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95937397T Active ES2136883T7 (es) 1994-10-19 1995-10-17 Nueva formulación mejorada de aminoglucósido para administración en forma de aerosol.

Country Status (11)

Country Link
US (1) US5508269A (es)
EP (1) EP0734249B3 (es)
JP (1) JP3474195B2 (es)
AT (1) ATE183080T1 (es)
AU (1) AU688166B2 (es)
CA (1) CA2179305C (es)
DE (1) DE69511374T3 (es)
DK (1) DK0734249T3 (es)
ES (1) ES2136883T7 (es)
GR (1) GR3031770T3 (es)
WO (1) WO1996012471A1 (es)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083922A (en) * 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US6076520A (en) * 1997-05-12 2000-06-20 Cooper; Emily L. Device for nasal therapeutic inhalation
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
IL140930A0 (en) 1998-08-07 2002-02-10 Emisphere Tech Inc Compounds and compositions for delivering active agents
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6387886B1 (en) * 1998-12-17 2002-05-14 Chiron Corporation Method for the treatment of severe chronic bronchitis (bronchietasis) with an aerosolized antibiotic
US6613352B2 (en) 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
AU2001235009B2 (en) 2000-02-11 2004-10-07 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
US8820316B2 (en) * 2000-02-11 2014-09-02 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
US7600511B2 (en) 2001-11-01 2009-10-13 Novartis Pharma Ag Apparatus and methods for delivery of medicament to a respiratory system
US8336545B2 (en) 2000-05-05 2012-12-25 Novartis Pharma Ag Methods and systems for operating an aerosol generator
US7971588B2 (en) 2000-05-05 2011-07-05 Novartis Ag Methods and systems for operating an aerosol generator
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US7214364B2 (en) * 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
DE122011100043I1 (de) * 2000-12-27 2011-12-15 Gilead Sciences Inc Inhalierbares aztreonam zur behandlung und vorbeugung von bakteriellen lungeninfektionen.
EP1598059A1 (en) 2001-05-18 2005-11-23 Chiron Corporation Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
US20030143162A1 (en) 2001-05-18 2003-07-31 Speirs Robert John Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
TR200401980T4 (tr) * 2001-07-02 2004-09-21 Chiesi Farmaceutici S.P.A. Aerosol olarak uygulama için en uygun hale getirilmiş tobramisin formülasyonu
US20040022740A1 (en) * 2001-07-10 2004-02-05 Baker William R. Macrolide formulations for inhalation and methods of treatment of endobronchial infections
PT1458360E (pt) * 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
ES2342463T3 (es) * 2002-03-01 2010-07-07 Chiesi Farmaceutici S.P.A. Formulacion superfina de formoterol.
US7607436B2 (en) * 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US8245708B2 (en) * 2002-05-07 2012-08-21 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
AU2003238846A1 (en) * 2002-05-31 2003-12-19 Childrens Hospital And Regional Medical Center Endobronchial delivery of antibiotic in individuals with impaired lung tissue or lung function
US6966649B2 (en) * 2002-08-12 2005-11-22 John H Shadduck Adaptive optic lens system and method of use
US20040045546A1 (en) * 2002-09-05 2004-03-11 Peirce Management, Llc Pharmaceutical delivery system for oral inhalation through nebulization consisting of inert substrate impregnated with substance (S) to be solubilized or suspended prior to use
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
NZ546821A (en) * 2003-10-15 2009-04-30 Pari Pharma Gmbh Liquid preparation containing tobramycin
ES2388420T3 (es) * 2004-05-17 2012-10-15 Gilead Sciences, Inc. Combinación de fosfomicina/aminoglucósido aerosolizada para el tratamiento de las infecciones respiratorias bacterianas
WO2006002178A1 (en) * 2004-06-18 2006-01-05 Novartis Vaccines And Diagnostics Inc. Methods of treatment of endobronchial infections
US20060073173A1 (en) * 2004-10-04 2006-04-06 Maria Banach Large-scale manufacturing process for the production of pharmaceutical compositions
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8546423B2 (en) * 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
WO2007041156A2 (en) 2005-09-29 2007-04-12 Nektar Therapeutics Antibiotic formulations, unit doses, kits, and methods
AU2013206401B2 (en) * 2005-09-29 2016-06-23 Novartis Ag Antibiotic formulations, unit doses, kits, and methods
EP3067047B1 (en) 2005-12-08 2022-04-20 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
US8337814B2 (en) * 2005-12-15 2012-12-25 Topical Sinus Therapeutics, Inc. Treatment of active infections, sinusitis, rhinitis, and related neurological disorders and related compositions
EP2012750B1 (en) * 2006-04-06 2018-02-21 Insmed Incorporated Methods for coacervation induced liposomal encapsulation and formulations thereof
EP2012801A4 (en) * 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc GEMCITABINE COMBINATION THERAPY
US20070286817A1 (en) * 2006-06-07 2007-12-13 Wyeth Treating cystic fibrosis with antibiotics via a swirler delivery
PE20080329A1 (es) * 2006-06-07 2008-04-09 Wyeth Corp Tratamiento de fibrosis cistica con antibioticos por via de una droga en aerosol
US20070286818A1 (en) * 2006-06-07 2007-12-13 Wyeth Treating cystic fibrosis with antibiotics via an aerosol drug
WO2007145866A1 (en) * 2006-06-07 2007-12-21 Wyeth Treating cystic fibrosis with antibiotics via a swirler delivery
US8957027B2 (en) * 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
WO2008033747A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
EP2063903A1 (en) * 2006-09-19 2009-06-03 Discovery Laboratories, Inc. Pulmonary surfactant formulations and methods for promoting mucus clearance
JP2008199905A (ja) * 2007-02-16 2008-09-04 Snow Brand Milk Prod Co Ltd 乳酸菌生残性向上剤
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
MX2010003263A (es) * 2007-09-25 2010-06-02 Novartis Ag Tratamiento de trastornos pulmonares con medicamentos aerosolizados tales como vancomicina.
MX2010012452A (es) * 2008-05-15 2011-03-15 Novartis Ag Star Suministro pulmonar de una fluoro-quinolona.
KR101959873B1 (ko) 2008-10-07 2019-03-19 랩터 파마슈티컬스 인코포레이티드 약동학 개선을 위한 에어로졸 플루오로퀴놀론 제형
CA2739893C (en) * 2008-10-07 2016-10-04 Mpex Pharmaceuticals, Inc. Inhalation of levofloxacin for reducing lung inflammation
RU2544010C2 (ru) 2009-02-27 2015-03-10 Энанта Фармасьютикалс, Инк. Ингибиторы вируса гепатита с
US20120018526A1 (en) * 2009-03-20 2012-01-26 Livia Tiba Method of creating salt aerosol for breathing by nebulizing an aqueous saline solution
US8431576B2 (en) 2009-06-25 2013-04-30 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
WO2011029059A1 (en) 2009-09-04 2011-03-10 Mpex Pharmaceuticals, Inc. Use of aerosolized levofloxacin for treating cystic fibrosis
SG181673A1 (en) 2009-12-14 2012-07-30 Chiesi Farma Spa Antibiotic microparticles for inhalation
EP2521711B1 (en) 2010-01-07 2017-08-16 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
EP2388008A1 (en) 2010-05-14 2011-11-23 Combino Pharm, S.L. Stable, preservative-free, aqueous formulation for the administration by aerosolization comprising tobramycin
ES2691671T3 (es) 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
KR102012418B1 (ko) * 2010-07-12 2019-08-20 셀리아 파마슈티칼즈 에이피에스 에어로졸화에 의한 토브라마이신의 투여에 의한 폐 감염의 치료
US20120202823A1 (en) 2010-12-23 2012-08-09 Alkermes, Inc. Multi-API Loading Prodrugs
TWI574687B (zh) 2011-01-03 2017-03-21 古利斯股份有限公司 具有鋅結合部份之刺蝟拮抗劑
WO2012135571A1 (en) 2011-04-01 2012-10-04 Curis, Inc. Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
KR20140025534A (ko) 2011-07-12 2014-03-04 카르데아스 파마 인코퍼레이티드 아미카신과 포스포마이신 조합물의 제형 및 인공호흡기 관련 폐렴(vap)과 인공호흡기 관련 기도(vat) 기관지염의 치료 방법 및 시스템
US8826904B2 (en) 2011-07-12 2014-09-09 Cardeas Pharma Corporation Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis
ES2532667T3 (es) 2011-09-12 2015-03-30 Meiji Seika Pharma Co., Ltd. Composiciones acuosas que contienen arbekacina
EP2790703B1 (en) 2011-12-15 2019-06-12 Alkermes Pharma Ireland Limited Samidorphan (alks 33) in combination with opioid agonists
JP5952912B2 (ja) 2011-12-15 2016-07-13 アルカーメス ファーマ アイルランド リミテッド 二級アミン化合物のプロドラッグ
GB201208080D0 (en) * 2012-05-09 2012-06-20 Norton Healthcare Ltd Tobramycin formulation
PL2852391T3 (pl) 2012-05-21 2022-04-11 Insmed Incorporated Układy do leczenia infekcji płuc
CN102949379B (zh) * 2012-11-14 2014-11-05 中山大学 硫酸奈替米星吸入粉雾剂及其制备方法
US10124066B2 (en) 2012-11-29 2018-11-13 Insmed Incorporated Stabilized vancomycin formulations
EP2968285A4 (en) 2013-03-13 2016-12-21 Flatley Discovery Lab COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
CN106459993A (zh) 2014-03-31 2017-02-22 德彪药业国际股份公司 Fgfr融合体
LT3466432T (lt) 2014-05-15 2020-12-28 Insmed Incorporated Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti
CA2959104A1 (en) 2014-08-26 2016-03-03 Hsf Pharmaceuticals Novel immunization agents and methods of use
KR20170095814A (ko) 2014-10-06 2017-08-23 플랫틀리 디스커버리 랩, 엘엘씨 트라이아졸로피리딘 화합물 및 낭성 섬유증의 치료 방법
WO2016089981A1 (en) * 2014-12-04 2016-06-09 Carefusion 2200, Inc. Breath-actuated nebulizer for medicine inhalation
CN105616345B (zh) * 2016-03-01 2018-08-21 上海方予健康医药科技有限公司 一种妥布霉素吸入组合物及其制备方法和用途
KR102398439B1 (ko) 2016-03-07 2022-05-16 이난타 파마슈티칼스, 인코포레이티드 B형 간염 항바이러스제
EP3512602B1 (en) 2016-09-16 2024-03-27 HSF Pharmaceuticals Inhibitors of heat shock factors (hsf) and uses thereof
SG11202001685TA (en) 2017-08-28 2020-03-30 Enanta Pharm Inc Hepatitis b antiviral agents
US12077827B2 (en) * 2017-09-29 2024-09-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for predicting the risk of developing pulmonary colonization/infection by Pseudomonas aeruginosa
US20210401968A1 (en) 2018-03-08 2021-12-30 Hsf Pharmaceuticals Sa Localized activation of virus replicatio boosts herpesvirus-vectored vaccines
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
JP7449275B2 (ja) 2018-05-02 2024-03-13 インスメッド インコーポレイテッド リポソーム薬物製剤の製造方法
BR112020022633A2 (pt) 2018-05-10 2021-05-04 Cis Pharma Ag copolímero biocompatível contendo moléculas de agente ativo múltiplas
CN113164466B (zh) 2018-09-11 2025-07-08 柯瑞斯公司 使用具有锌结合部分的磷酸肌醇3-激酶抑制剂的联合治疗
JP2022500466A (ja) 2018-09-21 2022-01-04 エナンタ ファーマシューティカルズ インコーポレイテッド 抗ウイルス剤としての官能化複素環
EP3653716A1 (en) 2018-11-19 2020-05-20 HSF Pharmaceuticals Replication-competent controlled alpha-herpesvirus virus vectors and uses therefore
GB2565941A (en) * 2018-11-27 2019-02-27 Norton Healthcare Ltd A process for preparing a formulation
US12558432B2 (en) 2019-10-30 2026-02-24 Cis Biopharma Ag Biocompatible polymeric drug carriers for delivering active agents
CN115003296A (zh) 2019-12-05 2022-09-02 弗拉特利发现实验室有限责任公司 用于治疗囊肿状纤维化的化合物及其治疗方法
US20240229065A1 (en) 2020-04-24 2024-07-11 Hsf Pharmaceuticals Sa Replication-competent controlled herpesviruses expressing a sars cov-2 antigen
US20230233514A1 (en) 2020-06-23 2023-07-27 Flagship Pioneering, Inc. Antiviral compounds and methods of using the same
US20220033383A1 (en) 2020-07-20 2022-02-03 Enanta Pharmaceuticals, Inc. Functionalized peptides as antiviral agents
JP2023551174A (ja) 2020-11-23 2023-12-07 エナンタ ファーマシューティカルズ インコーポレイテッド 新規スピロピロリジン誘導抗ウイルス剤
WO2023006993A1 (en) 2021-07-30 2023-02-02 Atmosr Fused amino pyridine or pyrimidine derivatives for the treatment of congenital central hypoventilation syndrome
CN114177140A (zh) * 2021-12-10 2022-03-15 卓和药业集团股份有限公司 一种硫酸奈替米星气雾剂
WO2025214935A1 (en) 2024-04-11 2025-10-16 Hsf Pharmaceuticals Sa Recombinant alphaherpesvirus vectors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424216A (en) * 1979-07-31 1984-01-03 The Rockefeller University Method for the reduction of mucin viscosity
JPH01283225A (ja) * 1988-05-10 1989-11-14 Toyo Jozo Co Ltd 牛呼吸器感染症治療用エアゾール製剤およびそれを用いる治療方法
US4906476A (en) * 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances

Also Published As

Publication number Publication date
EP0734249B1 (en) 1999-08-11
DE69511374D1 (de) 1999-09-16
AU688166B2 (en) 1998-03-05
ES2136883T7 (es) 2012-06-14
JP3474195B2 (ja) 2003-12-08
EP0734249B3 (en) 2011-12-21
CA2179305A1 (en) 1996-05-02
EP0734249A1 (en) 1996-10-02
DE69511374T2 (de) 2000-02-24
US5508269A (en) 1996-04-16
DE69511374T3 (de) 2012-04-12
DK0734249T3 (da) 1999-12-06
WO1996012471A1 (en) 1996-05-02
ATE183080T1 (de) 1999-08-15
AU3952295A (en) 1996-05-15
GR3031770T3 (en) 2000-02-29
CA2179305C (en) 2000-10-31
EP0734249A4 (en) 1997-09-10
JPH09511254A (ja) 1997-11-11

Similar Documents

Publication Publication Date Title
ES2136883T3 (es) Nueva formulacion mejorada de aminoglucosido para administracion en forma de aerosol.
AR043863A1 (es) Composiciones que contienen piperacilina y tazobactam, utiles para inyeccioines
HK1043732A1 (zh) 利用烟雾状抗生素治疗严重慢性支气管炎(支气管扩张)的方法
CA2452638A1 (en) Optimised formulation of tobramycin for aerosolization
GEP19991538B (en) Derivatives of Erytromycin and Pharmaceutical Composition on their Basis
PL319833A1 (en) Compounds and composition for carrying active media
AR010995A1 (es) Uso de la mupirocina, sales o esteres de la misma en la obtencion de medicamentos administrables via nasal y formulaciones farmaceuticas inclusiveformulaciones farmaceuticas administrables via nasal.
UY24813A1 (es) Nuevas preparaciones medicamentosas acuosas para la produccion de aerosoles libres de gas propulsor
PT1121102E (pt) Inibidores da topoisomerase aprisionados em lipossoma
ES2193726T3 (es) Formulaciones de aerosol medicinales.
ES2094539T3 (es) Preparacion farmaceutica y procedimiento para su preparacion.
BG103947A (en) Derivatives of 9-oxymerythromycin
BRPI9915480B8 (pt) azalídeos de 13 membros, composições farmacêuticas compreendendo os mesmos, método para sua preparação bem como seus usos.
DE69724991D1 (de) Behandlung von bronchitis mit diuridintretraphosphat
TW200608983A (en) Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
WO2002003998A3 (en) Macrolide formulations for inhalation and methods of treatment of endobronchial infections
MXPA03007748A (es) Composiciones que destruyen virus.
NZ510153A (en) Tan-1057 derivatives with reduced toxicity and their use in medicaments for treating bacterial infections in humans and mammals
AU5169790A (en) New concentrated aqueous emulsions, process for preparing them and their use in the field of pesticides
CA2236237A1 (en) Use of hyaluronic acid and corresponding salts for the preparation of an aqueous solution useful as intra-articular lavage liquid
CA2420640A1 (en) Combination preparations of 3-n-formyl hydroxy amino propyl phosphonic acid derivatives or 3-n-acetyl hydroxy amino propyl phosphonic acid derivatives together with special pharmaceutical active ingredients
DE59510583D1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid
FR2754824B1 (fr) Nouvelle composition contenant du chitosan
ES2092559T3 (es) Formulacion farmaceutica que contiene penciclovir.
AU1777595A (en) Methods for treating neurofibromatosis

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 734249

Country of ref document: ES